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Thymic neuroendocrine carcinoma
(carcinoid): What if octreotide
scanning is negative?
To the Editor:
I was interested to read Filosso and col-
leagues’ recent description1 of a case of
thymic neuroendocrine carcinoma (carci-
noid) successfully treated with neoadju-
vant radiotherapy and chemotherapy and
the somatostatin (sst2) analog octreotide.
Filosso and colleagues1 stated, “Neu-
roendocrine tumors, including thymic tu-
mors, express sst2 at immunohistochem-
istry.” Other than octreotide scanning
and computed tomography or magnetic
resonance imaging (which were clearly
useful in their case), they did not discuss
other methods of localizing these tumors.
This gives the impression that all thymic
neuroendocrine carcinomas may be de-
tected with octreotide scanning. How-
ever, although others have also reported
octreotide scanning to be of use in de-
tecting thymic neuroendocrine tumors,2,3
this is not always the case. A recent case
series found none of 12 cases to have
positive results for sst2 receptors.4 Thus
if results of octreotide scanning are neg-
ative, other methods may be needed for
accurately localization of both the pri-
mary tumor and any metastases to treat
cases of thymic neuroendocrine carci-
noma as successfully as did Filosso and
colleagues.1 Other such methods that
may be useful are positron emission to-
mographic scanning with fluorodeoxy-
glucose labeled with fluorine 18 and
Tscanning with metaiodobenzylguanidine
labeled with iodine 123.4,5 In 2 cases
briefly reported from Guy’s Hospital,5 1
patient underwent octreotide scanning,
with negative results. However, positron
emission tomographic scanning localized
metastases, and radiolabeled metaiodo-
benzylguanidine was used to treat these
metastases.
Donald Whitaker, FRCS(ED)
Department of Cardiothoracic Surgery
Guy’s Hospital
London SE1 9RT, United Kingdom
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Reply to the Editor:
I thank Whitaker for his interest in our
recently published article.1 The message of
this article was the feasibility and the effi-
cacy of a multidisciplinary (chemoradio-
therapy, surgery, and biologic therapy)
he Journal of Thoracic and Cardiovasculartreatment for a giant and biologically ag-
gressive thymic neuroendocrine tumor.
The patient underwent preoperative oc-
treotide scintigraphy with positive results,
the in vivo demonstration of the somatosta-
tin receptors presence in the neoplastic tis-
sue. It is widely known that neuroendo-
crine tumors can have negative results of
octreotide scintigraphy; in my own experi-
ence, I have observed several bronchial
carcinoids (both typical and atypical) with
negative results of octreotide scintigraphy
and without somatostatin receptors in sur-
gical specimens. In some of these cases,
positron emission tomographic (PET) scan
results were positive. Probably these cases
represent a more aggressive variant of neu-
roendocrine neoplasm, but further reports
are needed to confirm this hypothesis.
I agree with Whitaker’s suggestion to
use PET scan when results of octreotide
scintigraphy are negative in the preopera-
tive patient assessment. One must consider,
however, that PET scan is not widely avail-
able in my country, and the cost of this
procedure is still high. Had the patient I
described had negative results of octreotide
scintigraphy, I definitely would have con-
sidered PET or metaiodobenzylguanidine
scanning.
Pier Luigi Filosso, MD
University of Torino Italy
San Giovanni Battista Hospital
Department of Thoracic Surgery
Via Genova 3, 10126 Torino, Italy
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